Hyundai ADM Bio has demonstrated significant anti-metastatic efficacy of its novel drug Penetrium in preclinical studies for triple-negative breast cancer (TNBC). The drug uniquely targets the extracellular matrix (ECM), potentially overcoming traditional chemotherapy limitations by softening therapy-hardened barriers and preventing metastasis. Combination therapy with paclitaxel reduced tumor size by 36.22% and metastasis by 85.78% in mouse models.